Recently we reported the frequency of TP53 polymorphisms, including 72Pro and Ins16 alleles in a study of the contribution of germline TP53 mutations in French Canadian breast and/or ovarian cancer families tested negative for BRCA1 and BRCA2 mutations [25]. This evidence concerns the gene BRCA2 and ovarian carcinoma.